News
PRPO
30.45
+3.47%
1.02
Precipio Stock Gains Post Q2 Earnings, Revenue Momentum Strong
NASDAQ · 22h ago
Weekly Report: what happened at PRPO last week (0810-0814)?
Weekly Report · 5d ago
Precipio reports Q2 results
Seeking Alpha · 5d ago
*Precipio 2Q Loss $200,000 >PRPO
Dow Jones · 08/14 20:01
*Precipio 2Q Rev $7M >PRPO
Dow Jones · 08/14 20:01
Press Release: Precipio Announces Q2-2026 Financial Results
Dow Jones · 08/14 20:00
Weekly Report: what happened at PRPO last week (0803-0807)?
Weekly Report · 08/10 09:50
Weekly Report: what happened at PRPO last week (0727-0731)?
Weekly Report · 08/03 09:49
Precipio Schedules Q2 2026 Shareholder Update Call
TipRanks · 07/31 21:21
Weekly Report: what happened at PRPO last week (0720-0724)?
Weekly Report · 07/27 09:52
Weekly Report: what happened at PRPO last week (0713-0717)?
Weekly Report · 07/20 09:50
PRPO vs. NEO: Which Cancer Diagnostics Stock Is the Better Buy?
NASDAQ · 07/16 14:21
Weekly Report: what happened at PRPO last week (0706-0710)?
Weekly Report · 07/13 09:51
Weekly Report: what happened at PRPO last week (0629-0703)?
Weekly Report · 07/06 09:53
The Zacks Analyst Blog Highlights Caterpillar, Palo Alto Networks, Toyota Motor and Precipio
NASDAQ · 06/29 14:57
Weekly Report: what happened at PRPO last week (0622-0626)?
Weekly Report · 06/29 09:50
Top Analyst Reports for Caterpillar, Palo Alto & Toyota
NASDAQ · 06/26 20:16
Weekly Report: what happened at PRPO last week (0615-0619)?
Weekly Report · 06/22 09:56
Precipio Shareholders Back Board Nominees and Auditor
TipRanks · 06/15 21:22
Weekly Report: what happened at PRPO last week (0608-0612)?
Weekly Report · 06/15 09:57
More
Webull provides a variety of real-time PRPO stock news. You can receive the latest news about Precipio Inc through multiple platforms. This information may help you make smarter investment decisions.
About PRPO
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.